Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHER: Prophylactic Cancer Peptide Vaccine in Advanced ALK+ NSCLC
NCT05950139Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2024
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Incidence of treatment-related adverse events up to 2 years and Vaccine-specific immune response up to 2 years. Started May 2024; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05950139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950139.